Published in Nature on March 02, 1984
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science (1985) 7.70
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (1986) 5.25
HIV viral load markers in clinical practice. Nat Med (1996) 4.78
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med (1992) 4.71
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med (1993) 4.43
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 4.31
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet (1984) 3.77
Human T lymphotropic virus type III infection of human alveolar macrophages. Blood (1986) 3.66
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science (1984) 3.50
The acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.49
HTLV-III in cells cultured from semen of two patients with AIDS. Science (1984) 3.47
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol (1997) 3.27
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science (1985) 3.05
A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med (1989) 2.95
Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med (1984) 2.93
The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem (1998) 2.88
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med (1986) 2.53
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1988) 2.34
Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med (1986) 2.33
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med (1987) 2.31
Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med (1990) 2.29
The impact of HIV on chronic kidney disease outcomes. Kidney Int (2007) 2.22
Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. N Engl J Med (1985) 2.20
Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem (1995) 2.17
Improving the outcomes of care for patients with human immunodeficiency virus infection. N Engl J Med (1996) 2.13
Biological properties of a CD4 immunoadhesin. Nature (1990) 2.05
Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature (1987) 1.91
Findings in psychiatric consultations with patients with acquired immune deficiency syndrome. Am J Psychiatry (1985) 1.90
Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med (1990) 1.89
Seroepidemiology of human T-lymphotropic virus type III among homosexual men with the acquired immunodeficiency syndrome or generalized lymphadenopathy and among asymptomatic controls in Boston. Ann Intern Med (1985) 1.89
Human T-lymphotropic virus type III in high-risk, antibody-negative homosexual men. Ann Intern Med (1986) 1.88
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA (1989) 1.84
Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol (1987) 1.83
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med (1990) 1.82
CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 1.78
Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med (1994) 1.66
Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retroviruses (1987) 1.65
Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest (1989) 1.61
Mortality associated with mode of presentation in the acquired immune deficiency syndrome. J Natl Cancer Inst (1984) 1.59
Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis (1994) 1.55
The histiocytic disorders: a pathophysiologic analysis. Ann Intern Med (1981) 1.50
AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA (1989) 1.48
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem (2000) 1.46
Immune (gamma) interferon produced by a human T-lymphoblast cell line. Nature (1981) 1.45
The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study. AIDS (1990) 1.44
Quantitation of plasma human immunodeficiency virus type 1 RNA by competitive polymerase chain reaction. J Infect Dis (1992) 1.44
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol (1996) 1.43
HIV, HTLV-I, and CD4+ lymphocytes. Troubles in the relationship. JAMA (1994) 1.42
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med (1993) 1.42
Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol (1991) 1.41
HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood (2001) 1.40
Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. J Virol (1989) 1.38
Behavioral risk factors for HIV infection among homosexual men at a Boston community health center. Am J Public Health (1988) 1.37
Low sensitivity of ELISA testing in early HIV infection. N Engl J Med (1986) 1.37
In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci U S A (1986) 1.35
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene (2009) 1.35
Hematologic manifestations of the human immune deficiency virus (HIV). Semin Hematol (1988) 1.34
HTLV-III infection among health care workers. Association with needle-stick injuries. JAMA (1985) 1.31
The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood (1998) 1.30
Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol (1998) 1.28
Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells. J Virol (1990) 1.28
The clinical spectrum of the acquired immunodeficiency syndrome: implications for comprehensive patient care. Ann Intern Med (1985) 1.26
Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood (1994) 1.26
Epidemic of the acquired immunodeficiency syndrome: a need for economic and social planning. Ann Intern Med (1983) 1.24
Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/lymphadenopathy-associated virus infection. J Clin Microbiol (1986) 1.22
Treatment of patients with acquired immunodeficiency syndrome and associated manifestations. JAMA (1987) 1.21
Pathophysiology and management of HIV-associated hematologic disorders. Blood (1989) 1.20
CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type 2-infected lymphoid cells. J Virol (1990) 1.20
Preferences of homosexual men with AIDS for life-sustaining treatment. N Engl J Med (1986) 1.19
Antibodies to human T-lymphotropic virus type III and development of the acquired immunodeficiency syndrome in homosexual men presenting with immune thrombocytopenia. Ann Intern Med (1986) 1.19
Intestinal infection with Mycobacterium avium in acquired immune deficiency syndrome (AIDS). Histological and clinical comparison with Whipple's disease. Dig Dis Sci (1985) 1.19
Stromal cell-derived factor-1 alpha and stem cell factor/kit ligand share signaling pathways in hemopoietic progenitors: a potential mechanism for cooperative induction of chemotaxis. J Immunol (1998) 1.18
Pathogenesis of B cell lymphoma in a patient with AIDS. Blood (1986) 1.18
Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol (1987) 1.18
Antibodies to human T-lymphotropic virus type III (HTLV-III) in saliva of acquired immunodeficiency syndrome (AIDS) patients and in persons at risk for AIDS. Blood (1986) 1.17
Immunogenic nature of a Pol gene product of HTLV-III/LAV. Blood (1987) 1.17
HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood (2000) 1.12
Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiency virus type 1 (HIV-1). J Infect Dis (1990) 1.11